We read with interest the study published by Tang and coll.1 in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have “sepsis-induced coagulopathy”. The definition of severe COVID-19 was the presence of at least one of following: respiratory rate ≥30 breaths /min; arterial oxygen saturation ≤93% at rest; PaO2/FiO2 ≤300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.

Porfidia, A., Pola, R., Venous thromboembolism in COVID-19 patients, <<JOURNAL OF THROMBOSIS AND HAEMOSTASIS>>, 2020; (15 Apr): N/A-N/A. [doi:10.1111/jth.14842] [http://hdl.handle.net/10807/154106]

Venous thromboembolism in COVID-19 patients

Porfidia, Angelo
Primo
;
Pola, Roberto
Ultimo
2020

Abstract

We read with interest the study published by Tang and coll.1 in a recent issue of the Journal of Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital of Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe COVID-19 who have “sepsis-induced coagulopathy”. The definition of severe COVID-19 was the presence of at least one of following: respiratory rate ≥30 breaths /min; arterial oxygen saturation ≤93% at rest; PaO2/FiO2 ≤300 mmHg. The Authors of this study also reported that, among subjects not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose of 40-60 mg/day, for at least 7 days.
2020
Inglese
Porfidia, A., Pola, R., Venous thromboembolism in COVID-19 patients, <<JOURNAL OF THROMBOSIS AND HAEMOSTASIS>>, 2020; (15 Apr): N/A-N/A. [doi:10.1111/jth.14842] [http://hdl.handle.net/10807/154106]
File in questo prodotto:
File Dimensione Formato  
jth.14842.pdf

Open Access dal 01/05/2020

Tipologia file ?: Postprint (versione finale dell’autore successiva alla peer-review)
Licenza: Creative commons
Dimensione 1.39 MB
Formato Adobe PDF
1.39 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/154106
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 69
  • ???jsp.display-item.citation.isi??? 58
social impact